Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Now Included Among Recommended Regimens for Antiretroviral Treatment-Naive Individuals with HIV-1 Infection
The FDA recently approved the fixed-dose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (EVG/c/FTC/TAF) as a complete regimen for antiretroviral treatment (ART)-naive HIV-infected individuals 12 years or older. Based on efficacy and safety data from phase 3 randomized clinical trials, the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents will include EVG/c/FTC/TAF among the Recommended Initial Regimens for ART-naive adults and adolescents with estimated creatinine clearance ≥ 30 mL/min (AI). For more information, see the Panel’s statement on EVG/c/FTC/TAF.
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - Category: Infectious Diseases Source Type: news
More News: Clinical Trials | Department of Health | Health | HIV AIDS | Infectious Diseases | Truvada | Viread